Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: Comparison of different days, cycles and doses

Pharmacology and Toxicology

Volumn 87, Issue 5, 2000, Pages 223-228

  Silvennoinen, Raija ^a   Malminiemi, Kimmo ^a   Malminiemi, Outi ^a   Seppälä, Erkki ^a   Vilpo, Juhani ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; PHENYLACETIC ACID DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033724634     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2000.d01-78.x     Document Type: Article

References (34)

1. ABPI Compendium of data sheets and summaries of product characteristics. Datapharm Publications Ltd., London, UK, 1998, p.441.
2. Adair, C. G., D. T. Burns, A. D. Crockard & M. Harriott: Determination of chlorambucil in plasma using reversed-phase high-performance liquid chromatography. J. Chromatogr. 1985, 342, 447-451.
3. Adair, C. G., J. M. Bridges & Z. R. Desai: Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? Cancer Chemother. Pharmacol. 1986, 17, 99-102.
4. Adair, C. G. & J. C. McElnay: Studies on the mechanism of gastrointestinal absorption of melphalan and chlorambucil. Cancer Chemother. Pharmacol. 1986, 17, 95-98.
5. AHFS Drug Information 1997. American Hospital Formulary Service. Eds.: G. K. McEvoy, K. Litvak & O. H. Welsh Jr. American Society of Health-System Pharmacists, Inc., Bethesda, Maryland, USA, 1997, pp. 700-704.
6. Alberts, D. S., S. Y. Chang, H. S. Chen, B. J. Larcom & T. L. Evans: Comparative pharmacokinetics of chlorambucil and melphalan in man. Recent Results Cancer Res. 1980, 74, 124-131.
7. Benet, L. Z., S. Oie & J. B. Schwartz: Design and optimization of dosage regimens; pharmacokinetic data. In: Goodman and Gilman's The pharmacological basis of therapeutics, 9th edition. Eds.: Hardman, J. G., L. E. Limbird, P. B. Molinoff, R. W. Ruddon & A. G. Gilman. McGraw Hill, New York, USA, 1996, App II, p. 1727.
8. Bennett, J., D. Catovsky, M-T. Daniel, G. Flandrin, D. Galton, H. Gralnik & C. Sultan: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J. Clin. Pathol. 1989,42, 567-584.
9. Binet, J., A. Auquier, G. Digihiero, C. Chastang, H. Piguet, J. Goasguen, G. Vaugier, G. Potron, O. Colona, F. Oberling, M. Thomas, G. Tchernia, C. Jacquillat, P. Boivin, C. Lesty, M. Duault, M. Monconduit, S. Belabbes & S. Gremy: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48, 198-206.
10. Brown, R. D. & J. E. Manno: ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J. Pharm. Sci. 1987, 67, 1687-1691.
11. Chabner, B. A., C. J. Allegra, G. A. Curt & P. Calabresi: Antineoplastic agents. In: Goodman and Gilman's The pharmacological basis of therapeutics, 9th edition. Eds.: Hardman, J. G., L. E. Limbird, P. B. Molinoff, R. W Ruddon & A. G. Gilman. McGraw Hill, New York, USA, 1996, App II, p.1240.
12. Cheng, H. & W. J. Jusko: Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation. Pharmaceut. Res. 1988, 5, 156-164.
13. Dollery, C. In: Therapeutic drugs. 2nd edition. Vol 1. Churchill Livingstone, London, UK, 1999, p. C166.
14. Ehrsson, H., I. Wallin, S. O. Nilsson & B. Johansson: Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031). Eur. J. Clin. Pharmacol. 1983, 24, 251-253.
15. Ehrsson, H., I. Wallin, B. Simonsson, P. Hartvig & G. Öberg: Effect of food on pharmacokinetics of chlorambucil and its main metabolite, phenylacetic acid mustard. Eur. J. Clin. Pharmacol. 1984, 27, 111-114.
16. Efthymiopoulos, C., E. Piemont & L. Jung: MOM: a computer program for the automatic calculation of statistical moments in pharmacokinetic studies. Trends Pharmacol. Sci. 1989, 10, 480-483.
17. Farmer, P. B.: Metabolism and reactions of alkylating agents. Pharmacol. Therapeut. 1987, 35, 301-358.
18. Hartvig, P., B. Simonsson, G. Öberg, I. Wallin & H. Ehrsson: Interand intraindividual differences in oral chlorambucil pharmacokinetics. Eur. J. Clin. Pharmacol. 1988, 35, 551-554.
19. Heinzel, G., R. Woloszczak & P. Thomann: TopFit 2.0. Pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer, Stuttgart, 1993.
20. Hintze, J. L.: BMDP SOLO Statistical Programs. Version 4.0. BMDP Statistical Software Inc., Los Angeles, California, USA, 1991.
21. Hovinen, J.: A convenient synthesis of N,N-bis(2-chloroethyl)-p-aminophenylacetic acid, a major metabolite of the cancer chemotherapeutic agent chlorambucil. Acta chem. scand 1996, 50, 1174-1176.
22. Jack, D. B.: Handbook of clinical pharmacokinetic data. Macmillan Publishers Ltd., London, UK, 1992, p.44.
23. Jusko, W. J.: Guidelines for collection and analysis of pharmacokinetic data. In: Applied pharmacokinelics. Principles of therapeutic drug monitoring, 2nd edition. Eds.: W. E. Evans, J. J. Schentag & W. J. Jusko. Applied Therapeutics, USA, 1986, p.9.
24. Lind, M. J. & C. Ardiet: Pharmacokinetics of alkylating agents. Cancer Surv. 1993, 17, 157-188.
25. Loos, U., E. Musch, M. Malek & E. Riedel: Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration. Oncology 1991, 48, 334-342.
26. McLean, A., D. Newell & G. Baker: The metabolism of chlorambucil. Biochem. Pharmacol. 1976, 25, 2331-2335.
27. Metzler, C. M. & D. L. Weiner: PCNONLIN. Professional data analysis software. Version 3.0. Statistical Consultants Inc., Lexington, Kentucky, 1989.
28. Newell, D. R., A. H. Calvert, K. R. Harrap & T. J. McElwain: Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Brit. J. Clin. Pharmacol. 1983, 15, 253-258.
29. Oppitz, M. M., E. Musch, M. Malek, H. P. Rub, G. E. von Unruh, U. Loos & B. Muhlenbruch: Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay. Cancer Chemother. Pharmacol. 1989, 23, 208-212.
30. Rozman, C., E. Montserrat, J. Rodriquez-Fernandez, R. Ayats, T. Vallespi, R. Parody, A. Rios, D. Prados, M. Morey, F. Gomis, A. Alcala, M. Gutierrez, J. Maldonado, C. Gonzalez, M. Giralt, L. Hernandez-Nieto, A. Gabera & J. Fernandez-Ranada: Bone marrow histologie pattern - the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984, 64, 642-648.
31. Veng-Pedersen, P.: Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part I). Clin. Pharmacokin. 1989, 17, 345-366.
32. Vozeh, S., O. Schmidlin & W. Taeschner: Pharmacokinetic drug data. In: Clinical pharmacokinetics drug data handbook 1990. Ed.: G. J. Mammen. ADIS Press Ltd., Auckland, New Zealand, 1990, p.20.
33. Zakaria, M. & P. R. Brown: Rapid assay for plasma chlorambucil and phenyl acetic mustard using reversed-phase liquid chromatography. J. Chromatogr. 1982, 230, 381-389.
34. Zar, J. H.: Biostatistical analysis, 2nd edition. Prentice-Hall International Inc., Englewood Cliffs, New Jersey, USA, 1984, p.206.